Unlike some previous investigations, this analysis provides a clinicopathologically uniform cohort of newly diagnosed MGMT promoter methylated glioblastoma patients with exclusively IDH wild‐type tumors and a balanced control cohort. This evidence concerns the gene MGMT and glioblastoma.